Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.

Vellas B, Carrillo MC, Sampaio C, Brashear HR, Siemers E, Hampel H, Schneider LS, Weiner M, Doody R, Khachaturian Z, Cedarbaum J, Grundman M, Broich K, Giacobini E, Dubois B, Sperling R, Wilcock GK, Fox N, Scheltens P, Touchon J, Hendrix S, Andrieu S, Aisen P; EU/US/CTAD Task Force Members.

Alzheimers Dement. 2013 Jul;9(4):438-44. doi: 10.1016/j.jalz.2013.03.007.

PMID:
23809364
2.

Biomarkers for the early stages of clinical development in Alzheimer's disease.

Bordet R, Dartigues JF, Dubois B, Goehrs JM, Vernoux L, Semah F, Pasquier F, Bidaut-Mazel C; participatnts of Round Table n°3 if Giens XXV.

Therapie. 2010 Jul-Aug;65(4):285-90, 277-283. doi: 10.2515/therapie/2010040. Epub 2010 Sep 21. Review. English, French.

PMID:
20854749
3.

Biomarqueurs aux phases précoces de développement dans la maladie d'Alzheimer.

Bordet R, Dartigues JF, Dubois B, Goehrs JM, Vernoux L, Semah F, Pasquier F, Bidaut-Mazel C; les participants à la Table Ronde n°3 de Giens XXV.

Therapie. 2010 Jul-Aug;65(4):277-83. doi: 10.2515/therapie/2010039. French. No abstract available.

PMID:
27393108
4.

Antibody avidity measurement and immune complex dissociation for serological diagnosis of vertically acquired HIV-1 infection.

Simon F, Rahimy C, Krivine A, Levine M, Pepin JM, Lapierre D, Denamur E, Vernoux L, De Crepy A, Blot P, et al.

J Acquir Immune Defic Syndr. 1993 Feb;6(2):201-7.

PMID:
8433285

Supplemental Content

Loading ...
Write to the Help Desk